Institution Directory

Clinical trials at Johns Hopkins

Sites in Baltimore, MD

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1429

Shown on this page

Current sort

Live official records

Conditions: Kidney Transplant
Interventions: Sirolimus, Belatacept, Mycophenolate Mofetil, Tacrolimus (Group1), Anti-Thymocyte Globulin (ATG), Tacrolimus (Group 2); Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 20 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 15 more

Conditions: IBM, Inclusion Body Myositis, Myopathy, Myositis, ALS (Amyotrophic Lateral Sclerosis), PLS
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
Interventions: Maridebart cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 5,056 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 121
States / cities: Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 107 more

Conditions: Acute Myeloid Leukemia, Leukemia
Interventions: Quizartinib High Dose, Quizartinib Low Dose; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 11 more

Conditions: Peanut Allergy
Interventions: Tezepelumab, Peanut Oral Immunotherapy (OIT), Placebo for Tezepelumab; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Little Rock, Arkansas • Los Angeles, California • Baltimore, Maryland + 6 more

Conditions: Advanced Solid Tumor
Interventions: BG-C9074, Tislelizumab, Bevacizumab; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Los Angeles, California • Aurora, Colorado • Orlando, Florida + 2 more

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma, Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Blood Sample, Bone Scan, Computed Tomography, Entinostat, Ipilimumab, Nivolumab, Pharmacogenomic Study, Pharmacological Study, Positron Emission Tomography; Procedure · Other · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 5
States / cities: Duarte, California • New Haven, Connecticut • Baltimore, Maryland + 1 more

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Prostate Cancer Clinical Trials Consortium; Other
Eligibility: 18 Years and older · Male only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2037
U.S. locations: 3
States / cities: Baltimore, Maryland • New York, New York • Seattle, Washington

Conditions: Non-muscle-invasive Bladder Cancer
Interventions: Gemcitabine, Docetaxel, Bacillus Calmette Guerin; Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 870 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 229
States / cities: Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 163 more

Conditions: Breast Cancer
Interventions: Elacestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen; Drug
Lead sponsor: Stemline Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4,220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 176
States / cities: Daphne, Alabama • Chandler, Arizona • Gilbert, Arizona + 139 more

Conditions: Functional Recovery, Upper Extremity Vascularized Composite Allotransplantation
Interventions: Upper Extremity Vascularized Composite Allotransplantation (VCA); Procedure
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2037
U.S. locations: 9
States / cities: Los Angeles, California • New Haven, Connecticut • Louisville, Kentucky + 6 more

Conditions: Barrett Esophagus, Gastroesophageal Reflux, Esophageal Adenocarcinoma
Interventions: EsoCheck, EsoGuard; Device · Diagnostic Test
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 50 Years and older
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Aurora, Colorado • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more

About this Johns Hopkins institution page

What this page lists: ClinicalTrials.gov records that list Johns Hopkins in Baltimore, MD as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Johns Hopkins

Filter and sort this campus

Live official records

Advancing Transplantation Outcomes in Children

Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body Myositis

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Efficacy of Tezepelumab in Peanut Oral Immunotherapy

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

Intravesical BCG vs GEMDOCE in NMIBC

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Upper Extremity Vascularized Composite Allotransplantation: A Study Evaluating Safety, Functional Outcomes, and Patient-Reported Psychosocial Outcomes

Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms

About this Johns Hopkins institution page